secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2023-03-01T23:59:59+00:00
Accession:  0001193125-23-056553
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere Therapeutics prices $200M public offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Offering of 8,275,000 shares at $21.00/share and 1,250,000 pre-funded warrants at $20.9999 each.
- Gross proceeds ~$200M; net proceeds ~$187.6M after underwriting discounts and expenses.
- Proceeds to support commercial launch of FILSPARI (sparsentan) for IgAN and potential FSGS launch.
- Underwriters granted 30-day option to purchase up to 1,428,750 additional shares.
- Closing expected March 3, 2023; Jefferies, J.P. Morgan, BofA Securities, SVB Securities as joint book-runners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000119312523056553/0001193125-23-056553-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000119312523056553/d442636d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-056553

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer